- Having prospect for the development of simple, highly effective and safe sublingual vaccines
- Joint R&D Agreement for Regenerative Medicine Using Brown Adipocytes (for Slimming/weight loss)Concluded with Medical Corporation Tomoshibikai FIRE CLINIC
- FEF Pharmaceutical Co., Ltd. and Kyoto University have initiated a collaborative research project aimed at developing a novel treatment for lower extremity artery disease (LEAD).
- EPS Innovative Medicine’s company website has been newly created.
EPS Innovative Medicine
(Japan) Co., Ltd. is
A drug discovery company newly launched by the EPS Group on its 30th anniversary,
which aims to be a solution provider for the health industry.
For more information,
please feel free to contact us from below.